Developer of sustainable cell-free enzyme technology pursuing uses that include active ingredients for nutraceuticals and pharmaceuticals, CEO Michael Heltzen tell GEN Edge Click here to read the article GEN Edge: What’s in a Name - Out with Invizyne, In with eXoZymes0:12 Share on Facebook Share on Facebook Share on LinkedIn Share on LinkedIn Share on X Share on X Share on Pinterest Share on Pinterest Share via email Share via email
press clippings With NREL's Help, GCxN Company Readies for Initial Public Offering Read More at nrel.gov Read more